The three companies have joined forces to launch Aurobac Therapeutics, combining their respective strengths to develop a precision approach to treating infections.

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

Private Company Edition: In other $100m-plus venture capital rounds, Third Harmonic Bio emerged with $155m, including a new $105m series B round. Also, Europe- and Japan-focused Newton Biocapital launched its second VC fund with €50m in initial capital and a €150m fundraising goal. 

With more than 30 years’ experience in pharma and biotech, Clive Dix has seen the industry evolve and take on many challenges. He spoke to Scrip about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.